AstraZeneca’s novel immunotherapy for non-small cell lung cancer has been authorized for use by the FDA.
Browsing: non-small-cell lung cancer
This review summarizes the past decade of immunotherapy for non-small-cell lung cancer, gives an updated overview of trials in this field, and the context of future development in this exciting field.
Data from the CheckMate-227 trial has demonstrated that its cancer drug combination has reached its primary endpoint of progression-free survival.
Merck has extended its all-important lung-cancer lead, after combination Phase III trial demonstrates that Keytruda extends lung cancer survival.
In this article from Future Oncology, the author considers the data supporting the sequential use of available EGFR TKIs and key considerations for selection of first-line treatment.
In this interview with James Gulley find out about Phase I clinical trial for M7824 (a bifunctional fusion protein immunotherapy that targets both PD-L1 and TGF-beta), which has demonstrated preliminary effectiveness in patients with advanced solid tumors.
This review describes trials evaluating the monoclonal antibody pembrolizumab (an immunotherapy that blocks the interaction between PD-L1/PD-L2) as first-line therapy for advanced non-small-cell lung cancer.
Would you like to find out the key facts about non-small-cell lung cancer? We have…
Three single-nucleotide polymorphisms have been identified as viable candidates as biomarkers for the personalized monitoring and treatment of lung cancers.